Neisvac-C (N. Meningitidis Group C (Strain C11) Polysaccharide (De-O-Acetylated) Conjugated To Tetanus Toxoid)

Neisvac-C is a conjugate vaccine that targets meningococcal serogroup C and helps prevent serious invasive infections.

• Invasive disease caused by Neisseria meningitidis serogroup C: provides active immunization to reduce the risk of meningitis, septicemia, and related complications.
• Outbreak control in high‑risk settings: contributes to herd immunity and limits spread of serogroup C during community outbreaks.

• Neisvac-C contains a de‑O‑acetylated polysaccharide from Neisseria meningitidis group C chemically linked to tetanus toxoid. The conjugate enhances T‑cell dependent immune responses, prompting B‑cells to produce high‑affinity IgG antibodies that specifically recognize the group C capsular polysaccharide, thereby providing protective immunity against infection.

Neisvac-C is generally well tolerated, but injection‑related reactions and rare severe events can occur.

Common Side Effects

• Injection site pain: mild to moderate discomfort at the injection site.
• Redness or swelling: localized erythema or edema.
• Fever: transient low‑grade temperature rise.
• Headache: mild to moderate headache post‑vaccination.
• Fatigue: temporary tiredness.
• Myalgia: muscle aches near the injection area.

Serious or Rare Side Effects

• Anaphylaxis: severe allergic reaction requiring immediate medical attention.
• Guillain‑Barré syndrome: rare neurologic disorder with muscle weakness.
• Seizures: uncommon convulsive episodes.
• Severe hypotension: marked drop in blood pressure.
• Neurologic events: rare encephalopathy or meningitis‑like symptoms.
• Persistent high fever: prolonged febrile response beyond 48 hours.

Before administering Neisvac-C, consider the following precautions to ensure safe use.

• Allergy assessment: verify no known hypersensitivity to vaccine components or tetanus toxoid.
• Pregnancy: consult a healthcare professional; limited safety data are available.
• Immunocompromised patients: vaccine may elicit a reduced immune response.
• Concomitant vaccines: follow recommended intervals when co‑administering other immunizations.
• Age suitability: ensure the patient falls within the approved age range for the vaccine.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Neisvac-C may interact with other medical products; awareness of potential interactions helps maintain vaccine efficacy and safety.

Major Interactions (Avoid)

• Live vaccines: avoid co‑administration within 4 weeks to prevent interference.
• Immunoglobulin therapy: may diminish vaccine response if given within 3 months.
• Blood products: can affect immunogenicity if administered within 4 weeks.

Moderate Interactions (Monitor Closely)

• Antipyretics: may mask post‑vaccination fever, reducing clinical observation.
• Immunosuppressants: monitor antibody response as effectiveness may be reduced.
• Allergy medications: may alter the severity of local or systemic reactions.